Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee on the discontinuation of the benefit assessment procedure according to Section 35a SGB V Elosulfase alfa (reassessment of an orphan drug after exceeding the EUR 30 million turnover limit) (mucopolysaccharidosis, type IVA)

of 16 October 2025

The Federal Joint Committee (G-BA) decided the following at their session on 16 October 2025:

I. The benefit assessment procedure in accordance with Section 35a, paragraph 1, sentence 12 SGB V in conjunction with Chapter 5 Section 12, number 2 of the Rules of Procedure of the G-BA (reassessment of an orphan drug after exceeding the EUR 30 million turnover limit) for the proprietary medicinal product Vimizim with the active ingredient elosulfase alfa in the therapeutic indication "for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages" is discontinued.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 16 October 2025.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 16 October 2025

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken